ClinicalTrials.gg
Not yet recruitingNCT07273396Updated Dec 9, 2025

Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer

A Phase 1/2 interventional study of Pressurized intraperitoneal aerosol chemotherapy (PIPAC) using paclitaxel in Ovarian Neoplasms and Peritoneal Neoplasms, sponsored by Seoul National University Hospital. Not yet recruiting. Open to female participants aged 19 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Seoul National University Hospital · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
19 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Ovarian Neoplasms by Seoul National University Hospital — 5 open to participants now, 6 under way, 1 of them phase 3. Ovarian Neoplasms · Seoul National University Hospital.

Started
2026
the only one that year
Phase 1/2
Only one
of the 11
Registered
11th of 11
by date

Among the 11 studies in Ovarian Neoplasms by Seoul National University Hospital, this one is the only one that started in 2026, is the only one in phase 1/2, and was the 11th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

5 of the 11 studies in Ovarian Neoplasms by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 19 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Ovarian Neoplasms by Seoul National University Hospital, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the tolerance, safety, efficacy, and pharmacokinetics of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with paclitaxel in patients with platinum-resistant recurrent ovarian cancer and peritoneal carcinomatosis.

Read the detailed description

The Study Design is an interventional, non-randomized, sequential Phase 1/2a trial, where patients with platinum-resistant recurrent ovarian cancer(PROC) and radiologically confirmed peritoneal carcinomatosis will be enrolled.

All patients included in this study will receive PIPAC, laparoscopic aerosolization of paclitaxel under 12 mmHg pressure at 6-week intervals (up to 9 cycles) for treating PROC with peritoneal metastasis.

03

Conditions studied

  • Ovarian Neoplasms
  • Peritoneal Neoplasms

Keywords

  • Pressurized intraperitoneal aerosol chemotherapy
  • platinum-resistant recurrent
  • ovarian cancer
  • paclitaxel
04

Who can participate

Ages eligible
19 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: Women aged 19-85 years.
  2. Diagnosis: confirmed ovarian, fallopian tube, or peritoneal cancer.
  3. Platinum Status:

    • : Disease progression during platinum-based chemotherapy.
    • Resistant: Progression within 6 months (24 weeks) post-platinum therapy.
  4. Prior Therapies: ≥2 prior intravenous chemotherapies (may include paclitaxel).
  5. Treatment Options: Unresponsive to/ineligible for standard therapies (e.g., intolerance, ) and ineligible for surgical resection.
  6. : ≥1 measurable/evaluable peritoneal lesion per 1.1.
  7. : ≤1 asymptomatic distant metastasis (excluding retroperitoneal lymph nodes, pleural effusion, localized skin metastases).
  8. Imaging Confirmation: Peritoneal carcinomatosis confirmed by PET-CT/CT.
  9. Performance Status: 0-2.
  10. Pregnancy/:

    • Non-pregnant/non-lactating.
    • Contraception: Effective methods (IUD, sterilization) for 6 months post-PIPAC ( only).
  11. Organ Function:

    • Bone Marrow: >1,500/mm³, >100,000/mm³, >8.0 g/dL.
    • Liver: ≤1.5×, /ALT ≤1.5×ULN.
    • Kidney: Creatinine ≤1.5×ULN, >60 mL/min.
    • Lungs: FVC/ ≥70% predicted.
    • Coagulation: ≤1.5, aPTT ≤1.5×ULN.
  12. Consent: Signed .

Exclusion criteria

Exclusion Criteria:

  1. ≥2 distant (excluding retroperitoneal lymph nodes, pleural effusion, and localized skin metastases).
  2. to paclitaxel per approved domestic labeling.
  3. history to paclitaxel or PIPAC devices.
  4. Uncontrolled comorbidities per investigator judgment:

    • Class ≥II heart failure
    • cardiovascular disease (e.g., arrhythmia, myocardial infarction)
    • conditions (AIDS, diseases, immunosuppressive therapy)
    • Active / infection
    • Uncontrolled hypertension (systolic >160 mmHg or diastolic >100 mmHg)
    • Uncontrolled diabetes ( >8%)
    • Radiographic/clinical bowel obstruction.
  5. IV chemotherapy within 4 weeks prior to Cycle 1 PIPAC.
  6. \<3 months.
  7. Prior PIPAC therapy.
  8. Medically unfit for general anesthesia or laparoscopic surgery.
  9. Refusal of :

    - Medically acceptable methods:

    • Intrauterine device (failure rate \<1%)
    • Surgical sterilization (tubal ligation, hysterectomy, vasectomy; failure rate \<0.5%).
  10. Participation in another clinical trial within 1 month of screening.
  11. Other exclusionary factors per investigator discretion.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
53 participants (estimated)

Study arms

  • Experimental
    PIPAC-OVPAC group

    Drug: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) using paclitaxel

Interventions

  • DrugPressurized intraperitoneal aerosol chemotherapy (PIPAC) using paclitaxel

    All patients enrolled in this study receive PIPAC using paclitaxel under 12 mmHg at 6 weeks intervals (up to 9 cycles) 1. Phase 1 Design 1. Dose Escalation: Standard 3+3 design across 5 paclitaxel cohorts (20 → 40 → 67 → 100 → 140 mg/m²) using modified Fibonacci increments (100%, 67%, 50%, 40%). 2. Maximum tolerated dose(MTD) Determination * If ≥2/6 patients in cohort χ experience dose limiting toxicities(DLTs; Grade ≥3 toxicity per CTCAE v5.0, excluding manageable pain) and ≤1/6 in cohort χ-1, MTD = χ-1. * If no DLTs at 140 mg/m², Phase 1 concludes. 3. Dose Reduction * DLTs in 20 mg/m² trigger de-escalation to 10 mg/m². * If ≤1/6 DLTs in 10 mg/m² → RP2D; ≥2/6 DLTs → trial termination. 2. Phase 2 Design : Evaluates efficacy/safety of PIPAC at the RP2D in 23 patients, adjusting for 5-17% laparoscopic access failure.

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicities

    Dose limiting toxicities

    Time frame: Till 6 weeks after the first PIPAC in phase 1 study

  2. Maximum tolerated dose

    We consider dose escalation if 3 consecutive DLTs do not occur, or less than 1 in 6 DLTs occur, per standard 3+3 design. If DLT occurs in 2 or more of 6, the lower dose is considered the MTD if 1 or fewer DLTs are identified. In addition, the highest dose (140 mg/m2) is considered the MTD when 3 to 0 DLTs or 6 to 1 DLTs are identified at the highest dose. On the other hand, if the initial dose (20 mg/m2) is reduced to 10 mg/m2 to account for DLT, it is considered the MTD if no more than 1 in 6 develop DLT at that reduced dose.

    Time frame: During phase 1 study (up to 6 weeks)

  3. Recommended Phase 2 Dose

    Recommended Phase 2 Dose determined by dose limiting toxicities

    Time frame: During phase 1 study

  4. Disease control rate

    Disease control rate at the 9-week time point

    Time frame: During phase 2 study

Secondary outcomes

  1. Maximum concentration (Cmax)

    Cmax on pharmacokinetic evaluation of paclitaxel administered via pressurized intraperitoneal aerosol chemotherapy

    Time frame: During phase 1 study

  2. Time at which Cmax is observed (Tmax)

    Tmax on pharmacokinetic evaluation of paclitaxel administered via pressurized intraperitoneal aerosol chemotherapy

    Time frame: During phase 1 study

  3. Area under the curve (AUC)

    AUC on pharmacokinetic evaluation of paclitaxel administered via pressurized intraperitoneal aerosol chemotherapy

    Time frame: During phase 1 study

  4. Disease control rate

    Disease control rate at the 9-week time point

    Time frame: During phase 1 study

  5. Progression-free survival

    Time from the treatment start of pressurized intraperitoneal aerosol chemotherapy to the identification of progressive disease or the end of the study

    Time frame: During phase 1 and 2a studies

  6. Overall survival

    Time from the treatment start of pressurized intraperitoneal aerosol chemotherapy to cancer-related death or the end of the study

    Time frame: During phase 1 and 2a studies

  7. Peritoneal cancer index

    Peritoneal cancer index scores identified during pressurized intraperitoneal aerosol chemotherapy, which range from 0 to 39

    Time frame: During phase 1 and 2a studies

  8. Peritoneal Regression Grading Score

    Peritoneal Regression Grading Score examined by pathologic review; Peritoneal Regression Grading Score 1, complete response: Peritoneal Regression Grading Score 2, major response: Peritoneal Regression Grading Score 3, minor response; Peritoneal Regression Grading Score 4, no response

    Time frame: During phase 1 and 2a studies

  9. Changes in ascites volume

    Changes in ascites volume measured during pressurized intraperitoneal aerosol chemotherapy

    Time frame: During phase 1 and 2a studies

  10. CA-125

    Seum CA-125 levels, which are related to disease progression when more than 35 U/ml

    Time frame: Assessed at every visit during the study period

  11. human epididymis protein 4 (HE4)

    Serum HE4 levels, which are related to disease progression when more than 140 pmol/L

    Time frame: Assessed at every visit during the study period

  12. The Risk of Ovarian Malignancy Algorithm (ROMA) score

    ROMA score using serum CA-125 and HE4 levels, which are related to disease progression when more than 30%

    Time frame: Assessed at every visit during the study period

  13. EORTC QLQ-C30 questionnaire

    EORTC QLQ-C30 questionnaires measured during the study. The evaluation range for each item is from 0 to 100.

    Time frame: During phase 1 and 2a studies

  14. EORTC QLQ-OV28 questionnaire measured during the study

    EORTC QLQ-OV28 questionnaire measured during the study. The evaluation range for each item is from 0 to 100.

    Time frame: During phase 1 and 2a studies

  15. Safety evaluation

    Safety evaluation per CTCAE v5.0, including treatment-related adverse events and surgical complications. The evaluation range for each item is from grade 1 to grade 5.

    Time frame: During phase 1 and 2a studies

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Apr 2030, 51 months later.

Of 57 non-industry phase 1/2 interventional studies under Ovarian Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 110. This study's planned 51 months is below that.

Counting every sponsor, half of 173 studies reached it within 65 months; a quarter within 44 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2025
First posted
Dec 9, 2025
StartEst.
Jan 1, 2026
Primary completionEst.
Apr 30, 2030
CompletionEst.
Aug 31, 2030
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07273396
Responsible party
Hee Seung Kim (Professor, Seoul National University Hospital) — Principal investigator
First posted
Dec 9, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
Apr 30, 2030 (estimated)
Completion
Aug 31, 2030 (estimated)
Last update
Dec 9, 2025

Study contacts

Hee Seung Kim, MD, PhD
Contact
bboddi0311@snu.ac.kr
82-02-2072-4863
Hee Seung Kim, MD, PhD
principal investigator · Seoul National University College of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion